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A B S T R A C T
Objective: To compare health outcomes following initiation of antiretroviral therapy (ART) for
asymptomatic HIV-infected pregnant women at different CD4 levels.
Methods: We analyzed data from 706 asymptomatic HIV-infected Ethiopian women initiating ART during
pregnancy between February 2012 and October 2016. The outcomes evaluated were CD4 gain, CD4
normalization (CD4 count 750 cells/mm3) and occurrence of HIV-related clinical events after twelve
months of treatment.
Result: On average, CD4 count (cells/mm3) increased from 391 (95% CI: 372–409) at baseline to 523 (95%
CI: 495–551) after twelve months of treatment. Rate of CD4 gain was higher among women with baseline
CD4 between 350 and 499 compared to CD4 500 (207 versus 6, p < 0.001). But women with baseline
CD4 between 350 and 499 could not catch up with women with CD4 500. Women with baseline CD4
500 had signiﬁcantly higher likelihood of achieving CD4 normalization as compared to those with CD4
between 350 and 499 (AOR = 0.32, 95% CI: 0.13–0.76). No strong evidence of differential risk in the
occurrence of HIV-related clinical events.
Conclusion: Starting ART for asymptomatic HIV-infected women with CD4 count 500 cells/mm3 was
beneﬁcial to preserve or recover immunity after 12 months of treatment in a resource limited setting.
© 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Antiretroviral therapy (ART) is effective in reducing mortality
(Detels et al., 1998), and preventing mother-to-child transmission
(MTCT) (CDC, 1994; Connor et al., 1994) and sexual transmission of
HIV (Cohen et al., 2011). However, the optimal time to start
treatment has been a topic of debate (WHO, 2016), as a result, HIV
treatment guidelines have been regularly revised to balance risks
and beneﬁts of treatment. Initiation of ART immediately after
diagnosis is currently recommended (WHO, 2016; Günthard et al.,
2016; Ryom et al., 2016) following reports of clinical trials
demonstrating the beneﬁt of starting ART as early as possible* Corresponding author at: Kochi, 05 Jimma, P. O. Box 378, Ethiopia.
E-mail address: yohannesejigu@yahoo.com (Y. Ejigu).
https://doi.org/10.1016/j.ijid.2019.02.019
1201-9712/© 2019 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).(Kitahata et al., 2009; Group TAS, 2015; Group ISS, 2015; O’Connor
et al., 2016).
The effectiveness of ART in actual clinical settings might be
inferior to what is reported by clinical trials, because clinical trial
participants are more likely to be adherent to treatment than those
treated in actual program settings. The beneﬁt of early ART might
even be very minimal among young asymptomatic adults with
high level of CD4 count, as they have poor treatment adherence
and retention (Nachega et al., 2014; Grimsrud et al., 2015; Hu et al.,
2017), which could increase drug resistance (Meresse et al., 2014),
and impact the potential beneﬁt of early ART (Hu et al., 2017). In
fact, a sub-group analysis of a clinical trial among adults aged
below 30 years with CD4 count above 500cells/mm3 showed that
those initiated treatment and those deferred treatment have
similar rate of disease progression in the ﬁrst 18 months
(Schechter, 2018). This ﬁnding demonstrates that the beneﬁt ofciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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observational studies are essential to clarify concerns of early
initiation of ART. There are also reports indicating a greater risk of
adverse outcomes (Nansseu and Bigna, 2017; Jose et al., 2014)
associated with early ART initiation. Although newest antiretrovi-
ral drugs are more tolerable and have fewer side effects, they are
not commonly used in low income settings.
The burden of HIV/AIDS in Ethiopia is substantial. It is
estimated that 665,116 (1.1%) adults were living with the virus in
2016 and the majority (61.5%) were women (UNAIDS, 2016). At
the time of the study, indication to start ART for adults in Ethiopia
was based on CD4 count or disease progression. However,
pregnant women were started on ART up on diagnosis to prevent
mother-to-child transmission (Federal HIV Prevention and
Control Ofﬁce of Ethiopia, 2014). The CD4 count threshold for
initiating treatment for asymptomatic adults was 350 cells/mm3,
but was subsequently increased to 500 cells/mm3 in 2013, and
ART was recommended for all HIV infected adults in 2017 (Federal
Minstry of Health Ethiopia, 2017). The recommended type of ART
has also been regularly revised; at the time of the study, a
combination of tenofovir, lamivudine and efavirenz (TDF-3TC-
EFV) was the preferred ﬁrst line ART. Prophylaxes including co-
trimoxazole and isoniazid preventive therapy have been routinely
provided to prevent opportunistic infections. Treatment response
was monitored by CD4 count measured every six months (Federal
Ministry of Health Ethiopia, 2017). Evaluating the health beneﬁts
of ART for HIV-infected but asymptomatic Ethiopian women with
high level of CD4 counts is important. To our knowledge, there are
no previous Ethiopian studies addressing these questions.
Therefore, the main objective of our study was to evaluate the
clinical and immunological outcomes of asymptomatic HIV-
infected pregnant women who initiated ART at different CD4
levels in Ethiopia.Figure 1. Flow diagram showing study inclusion and exclusions.
Legend: ART: antiretroviral therapy, WHO: World Health Organization.Materials and methods
Study population
The study was conducted in three hospitals and six health centers
in Addis Ababa, Ethiopia. Information was obtained from clinical
charts and ART databases of HIV-infected pregnant women attending
prenatal care follow-up between February 2012 andOctober2016.The
clinical charts of 926 HIV-infected women who initiated ART during
pregnancy were reviewed. We excluded HIV-infected pregnant
women who had missing information about the type or timing of
ART initiation, baseline CD4 count and WHO stage at the time of ART
initiation. Women with HIV related clinical symptoms at the time of
ART initiation, and those who did not return after HIV diagnoses were
also excluded from the analysis. This left 706 HIV-infected asymp-
tomatic pregnant women eligible for analysis of prospective HIV-
related clinical events. Follow-up CD4 measurement was available for
668 women after six months and 297 women after twelve months of
ART initiation (Figure 1). This historical chart review was regarded as
clinical practice and outcome assessment and therefore did not
require written consent. The study was approved by the Norway
Regional Committees of Medical and Health Research Ethics of South/
East Norway, Jimma University Ethical Review Board,and Addis Ababa
City Administration Health Bureau.
Exposure variables
The main exposure variable was baseline CD4 count, which was
measured at the time of ART initiation. Baseline CD4 count was
categorized as less than 350 cells/mm3, between 350 and 499 cell/
mm3 and 500 cells/mm3 or more. We also evaluated the role of the
type of ART regimen. According to the Ethiopian treatment
guideline, the ﬁrst drug of choice was a combination of tenofovir,
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combination of tenofovir, lamivudine and nevirapine (TDF-3TC-
NVP), zidovudine, lamivudine and nevirapine (ZDV-3TC-NVP) and
zidovudine, lamivudine and efavirenz (ZDV-3TC-EFV). We catego-
rized the type of ART as TDF-3TC-EFV compared to all other ART
types (TDF-3TC-NVP, ZDV-3TC-NVP and ZDV-3TC-EFV).
Outcomes
The outcomes evaluated were average CD4 gain, CD4 normali-
zation and incidence of HIV-related clinical events after twelve
months of treatment. To deﬁne CD4 normalization, different
studies used different cutoff points, ranging from 500 to 900 cells/
mm3 (Gras et al., 2007; Le et al., 2013; García et al., 2004). Two
Ethiopian studies reported 723 and 775 cells/mm3 as median CD4
counts of HIV-free healthy Ethiopian adults (Tsegaye et al., 1999;
Abuye et al., 2005). We therefore deﬁned CD4 normalization as
achieving CD4 counts of at least 750 cells/mm3. The WHO clinical
staging categorizes HIV infection into four stages (stage I–IV), stage
one indicates that the patient has no HIV-related clinical
symptoms or mild symptoms, and stage four indicates severe
form of HIV-related illnesses including malignancies (WHO, 2013).
Long-term outcomes, such as AIDS-deﬁning illnesses and death
were rare, in part due to the short follow-up period. As a result,
occurrences of any WHO stage II–IV clinical events during our
follow-up period were combined for the analysis.
Covariates
Additional information was gathered on maternal background
characteristics likely to be associated with maternal immunologicTable 1
Characteristics of 706 HIV infected asymptomatic pregnant Ethiopian women by basel
Characteristics Total B
(n = 706) <
(n
Age in years (median + IQR) 28 (25–30) 2
Gestational age in weeks at ART initiation (median + IQR) 20 (15–27) 2
Marital status
Married 659 (93) 3
Others 44 (6) 3
Unknown 3 (0.4) 2
Educational status
No education 60 (9) 2
Primary 188 (27) 9
Secondary 188 (27) 1
Higher 51 (7) 3
Unknown 219 (31) 11
Baseline weight in kg (median  IQR) 56 (50–64) 5
Hemoglobin in mg/dl (median  IQR) 12 (11–13) 1
Adherence to treatment
Good 612 (87) 3
Fair 38 (5) 2
Poor 42 (6) 2
Unknown 14 (2) 6
Types of ART initiated
TDF-3TC-EFV 569 (81) 2
Other ART typesc 137 (19) 11
Data are n (%) or median (IQR). ZDV: zidovudine, 3TC: lamivudine, NVP: nevirapine, EF
a Statistical tests did not consider missing values.
b Kruskal-Wallis tests, the rest are chi-square test results.
c Other type of ARTs which include: TDF-3TC-NVP, ZDV-3TC-NVP or ZDV-3TC-EFV.and clinical outcomes. These included age, gestational week, level
of education (no education, primary, secondary and tertiary),
marital status (married and other), and weight in kilograms at the
time of treatment initiation. We also gathered information on
hemoglobin level (mg/dl) at the time of treatment initiation and
self-reported adherence to treatment (missing less than 5% of the
prescribed pills, categorized as “good”, missing between 5 to 20%
“fair” and missing more than 20% “poor”).
Statistical analysis
We compared background characteristics of women by baseline
CD4 category using chi-square for categorical covariates or
Kruskal-Wallis test for continuous covariates. We used linear
regression to examine the associations of baseline CD4 level and
types of ART initiated with change in CD4 count at six and twelve
months, reporting mean difference and 95% conﬁdence intervals
(CIs). We ran logistic regression to evaluate associations of baseline
CD4 count and type of ART regimen with the probability of CD4
normalization, reporting odds ratio (OR) and 95% CIs. Cox-
proportional hazard regression model was used to evaluate
associations of baseline CD4 level and type of ART regimen with
incident HIV-related clinical events, reporting hazard ratios (HRs)
and 95% CIs. We censored follow-up time for each woman at the
ﬁrst registration of a WHO stage II to stage IV HIV-related clinical
event, at the last visit, treatment interruption for more than 3
months, or after twelve months (end of follow-up). The
multivariable analyses were adjusted for known covariates
including age, gestational age, weight, marital status, education,
hemoglobin level and adherence to treatment. In addition, baseline
CD4 count and type of ART were adjusted for each other. Covariatesine CD4 count category.
aseline CD4 category
350 cells/mm3
 = 373)
350–499 cells/mm3
(n = 145)
>500 cells/mm3
(n = 188)
P-valuea
8 (25–30) 28 (25–30) 27 (24–30) 0.02b
1 (16–28) 20 (15–26) 19 (13–26) 0.04b
40 (91.2) 137 (94.5) 182 (96.8) 0.04
1 (8.3) 7 (4.8) 6 (3.2)
 (0.5) 1 (0.7) 0 (0)
6 (7.0) 15 (10.3) 19 (10.1) 0.54
6 (25.7) 40 (27.6) 52 (27.7)
03 (27.6) 35 (24.1) 50 (26.6)
2 (8.6) 7 (4.8) 12 (6.4)
6 (8.6) 48 (33.1) 55 (29.3)
6 (50–62.5) 56 (51–62) 56 (50–65) 0.87b
2 (11–13) 12 (11–13) 12 (12–13) 0.001b
18 (85.3) 130 (89.7) 164 (87.2) 0.47
1 (5.6) 7 (4.8) 10 (5.3)
8 (7.5) 6 (4.1) 8 (4.3)
 (1.6) 2 (1.4) 6 (3.2)
58 (69.2) 137 (94.5) 174 (92.6) <0.001
5 (29.8) 8 (5.5) 14 (7.4)
V: efavirenz, TDF: tenofovir, ART: antiretroviral therapy, IQR: interquartile range.
Figure 3. Median CD4 count during follow-up by type of ART regimen initiated in
asymptomatic HIV infected pregnant women.
Legend: CD4 count measurement was available for 706 women at baseline, 668
after six months and 297 at twelve months. Of these, 569 women at the start of ART,
538 after six months and 130 after twelve months were on TDF-3TC-EFV.
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variables. Most of the covariates had some missing values (ranging
from 31% for level of education to 2% adherence to treatment). We
therefore imputed missing values of covariates using chained
equations, imputing a total of 20 datasets. The imputation model
included all exposures, covariates, and outcome variables. We
observed similar results in the multiple imputation and complete-
case analyses. We report the results based on the imputed data as
main results, while the ﬁndings from the complete-case analysis
are presented in the supplement. The analyses were conducted
using STATA version 13 (Stata Corp., College Station, TX).
Result
A total of 706 HIV-infected asymptomatic (WHO Stage I)
women initiating ART during pregnancy were included in the
analysis of occurrence of HIV-related clinical events. Background
characteristics of women included (n = 706) and excluded (n = 220)
from the analysis were largely similar, except that excluded
women were younger and less compliant to treatment (Supple-
mental Table 1). Median age at ART initiation was 28 years (IQR:
25–30) and median gestational week at initiation was 20 weeks
(IQR: 15–27). The majority of women (80.5%) initiated TDF-3TC-
EFV. Women with baseline CD4 count 500 cells/mm3 were
younger and had higher hemoglobin level than women with CD4
below 500 cells/mm3. The distributions of other background
characteristics were largely similar across baseline CD4 levels
(Table 1). The distribution of background characteristics of the
subsample of women included in the evaluation of CD4 recovery at
6 months (n = 668) and 12 months (n = 297) after treatment
initiation is presented in Supplemental Table 2.
CD4 count recovery
On average, CD4 count increased from 391 (95% CI: 372–
409) cells/mm3 at the time of ART initiation, to 497 (95% CI: 478–
515) cells/mm3 after six months, and to 523 (95% CI: 495–
551) cells/mm3 after twelve months. We observed a decrease in
the CD4 count in 20% of the women after six months and 18% of the
women after twelve months. The median CD4 count measured
during follow-up according to baseline CD4 category and type of
ART is shown in Figures 2 and 3. The average CD4 gains after twelveFigure 2. Median CD4 count during follow-up by baseline CD4 count category in
asymptomatic HIV infected pregnant women.
Legend: CD4 count measurement was available for 706 women at baseline, 668
after six months and 297 at twelve months. Of 706 women,179 women had baseline
CD4 500 cells/mm3 and more,137 women had baseline CD4 350–499 cells/mm3 and
352 women had baseline CD4 less than 350 cells/mm3.months were 175 cells/mm3 (SD = 187) among women with
baseline CD4 below 350 cells/mm3, 207 cells/mm3 (SD = 162)
among women with baseline CD4 between 350 and 499 cells/
mm3, and 6 cells/mm3 (SD = 211) among women with baseline CD4
of 500 cells/mm3 or more (p < 0.001). On average, CD4 count after
twelve months reached 390, 624, and 698 cells/mm3 for women
with baseline CD4 counts below 350, 350 to 499 and 500 cells/mm3
or more respectively. After twelve months of treatment, a CD4
count of above 500 cells/mm3was achieved by 22%, 75% and 82% of
women with baseline CD4 below 350, 350 to 499 and 500 cells/
mm3 or more respectively.
We also evaluated CD4 normalization, which was deﬁned as
reaching CD4 count of 750 cells/mm3 or more. CD4 normalization
was achieved by 18% of women after twelve months. As compared
to those with baseline CD4 count less than 500 cells/mm3, a higher
proportion of women with baseline CD4 count of 500 cells/mm3 or
more achieved CD4 normalization after twelve months (43.6%
versus 8.6%, p < 0.001).
Inadjustedregressionanalysis, treatment initiationat lowlevelof
CD4 count was associated with higher CD4 gains during follow-up.
For example, compared to women with baseline CD4 count of 500
cells/mm3 or more, those with baseline CD4 count between 350 and
499 cells/mm3 had a larger CD4 gain after six (adjusted mean
difference = 142 cells/mm3, 95% CI: 101, 183) and twelve months
(adjusted mean difference = 207 cells/mm3, 95% CI: 140, 275)
(Table 2). Compared to TDF-3TC-EFV, women who initiated other
types of ARTs had lower CD4 gains after twelve months (adjusted
mean difference = 80 cells/mm3, 95% CI: 140, 21) (Table 2).
After adjusting for relevant covariates, we found that higher
baseline CD4 count was positively associated with CD4 normali-
zation following ART in these asymptomatic women. Compared to
women with CD4 count of 500 cells/mm3 or more at treatment
initiation, a lower proportion of women with baseline CD4 count
between 350 and 499 cells/mm3 achieved CD4 normalization after
six (adjusted OR = 0.10, 95% CI: 0.04–0.24) and twelve months
(adjusted OR = 0.32, 95% CI: 0.13–0.76) (Table 3). We observed no
strong evidence that the likelihood of CD4 normalization differed
according to type of ART regimen (Table 3).
Clinical outcomes
A total of 706 pregnant women who contributed 682 person-
years of follow-up were included in the analysis of clinical events.
Table 2
Association of baseline CD4 count and ART regimen with CD4 count gain from baseline to six and twelve months follow-up in asymptomatic HIV infected pregnant women.
Exposure variables CD4 count gain (cells/mm3) at six months (N = 668) CD4 count gain (cells/mm3) at 12 months (N = 297)
n Mean (SD) Unadjusted β(95%CI) Adjusted β(95%CI)a n Mean (SD) Unadjusted β(95%CI) Adjusted β(95%CI)a
Baseline CD4 (cells/mm3)
500 179 4.5 (224) Reference Reference 78 6 (211) Reference Reference
350–499 137 130 (152) 134 (97, 172) 142 (101, 183) 66 207 (162) 201 (139, 264) 207 (140, 275)
<350 352 158 (141) 162 (132, 193) 173 (139,208) 153 175 (187) 169 (118, 221) 200 (141, 259)
Type of ART
TDF-3TC-EFV 538 106 (185) Reference Reference 235 144 (210) Reference Reference
Other ART typesb 130 121 (174) 16 (19, 51) 29 (65, 7) 62 111 (178) 33 (90, 24) 80 (140, 21)
ART: antiretroviral therapy, TDF-3TC-EFV: a combination of tenofovir, lamivudine and efavirenz.
a The regression analyses were adjusted for age at treatment initiation, gestational age at ART initiation, weight at treatment initiation, marital status, level of education,
hemoglobin level and treatment adherence. In addition, baseline CD4 count and type of ART were adjusted for each other.
b Other type of ARTs include: ARTs comprised of TDF-3TC-NVP, ZDV-3TC-NVP or ZDV-3TC-EFV.
Table 3
Association of baseline CD4 count and type of ART regimen with CD4 normalization (CD4 750 cells/mm3) at six and twelve months in asymptomatic HIV infected pregnant
women.
Exposures CD4 normalization at six months (n = 668) CD4 normalization at 12 months (n = 297)
n/N(%) Unadjusted OR (95%CI) Adjusted OR (95%CI)a n/N(%) Unadjusted OR (95%CI) Adjusted OR(95%CI)a
Baseline CD4 (cells/mm3)
>500 65/179 (36) 1 1 34/78 (44) 1 1
350–499 8/137 (6) 0.11 (0.05–0.24) 0.10 (0.04–0.24) 13/66 (20) 0.32 (0.15–0.67) 0.32 (0.13–0.76)
<350 9/352 (3) 0.05 (0.02–0.10) 0.06 (0.03–0.13) 6/153 (4) 0.05 (0.02–0.13) 0.06 (0.02–0.18)
Type of ART
TDF-3TC-EFV 78/538 (15) 1 1 50/235 (21) 1 1
Other ART typesb 4/130 (3) 0.19 (0.07–0.52) 0.43 (0.12–1.63) 3/62 (4.8) 0.19 (0.06–0.63) 0.48 (0.12–2.00)
OR: odds ratio, ART: antiretroviral therapy, TDF-3TC-EFV: a combination of tenofovir, lamivudine and efavirenz.
a The regression analyses were adjusted for age at ART initiation, gestational age at ART initiation, weight at ART initiation, marital status, level of education, hemoglobin
level and treatment adherence. In addition, baseline CD4 count and type of ART were adjusted for each other.
b Other type of ARTs: include ARTs composed of TDF-3TC-NVP, ZDV-3TC-NVP or ZDV-3TC-EFV.
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interrupted for 3 or more months and one woman was censored
after having died. During the follow-up, 24 women experienced
HIV-related clinical events. Of these, 20 (2.9%) were WHO stage II,
three (0.5%) were WHO stage III and one (0.2%) was WHO stage IV.
Incidence rate of HIV-related clinical events was 3.5 per 100
person-years of follow-up (95% CI: 2.4–5.2 per 100 person-years).
Incidence of HIV-related event was 5.3 per 100 person-years,
among women with baseline CD4 count below 350 cells/mm3; 2.2
per 100 person-years among women with baseline CD4 count
between 350 and 499 cells/mm3; and 1.1 per 100 person-years
among women with CD4 count >500 cells/mm3 (p = 0.01).
In adjusted analysis, the incidence of HIV-related clinical events
among women with baseline CD4 of 500 cells/mm3 or more was
not signiﬁcantly different from women with a baseline CD4 countTable 4
Association of baseline CD4 count and type of ART with occurrence of HIV-related clinical 
years.
Exposures Person years of follow-up Number of e
Baseline CD4 (cells/mm3)
>500 184 2 
350–499 141 3 
<350 357 19 
Type of ART
TDF-3TC-EFV 553 14 
Other ART typesb 129 10 
HR: hazard ratio, ART: antiretroviral therapy, TDF-3TC-EFV: a combination of tenofovir
a The regression analyses were adjusted for age at treatment initiation, gestational ag
hemoglobin level and treatment adherence. In addition, baseline CD4 count and type o
b Other type of ARTs: include ARTs composed of TDF-3TC-NVP, ZDV-3TC-NVP or ZDVbetween 350 and 499 cells/mm3 (adjusted HR = 2.01, 95% CI: 0.35–
12.55), or from women with a baseline CD4 count of less than
350 cells/mm3 (adjusted HR = 4.10, 95%CI: 0.91–18.47) (Table 3).
Similarly, the association between type of ART and incidence of
clinical events observed in unadjusted analysis was attenuated in
adjusted analysis (Table 4).
Discussion
Our ﬁndings indicated that starting ART for asymptomatic HIV-
infected pregnant women before their CD4 count falls below
500 cells/mm3 is beneﬁcial for CD4 normalization (CD4 recovery to
750 cells/mm3 or more) in resource-limited settings. Women who
started ARTat lower baseline CD4 count (<500 cells/mm3) could not
catch up with those who had higher baseline CD4 count (500 cells/events in asymptomatic HIV infected pregnant women who contributed 682 person-
vents Unadjusted HR (95% CI) Adjusteda HR (95% CI)
1 1
1.95 (0.33–11.65) 2.01 (0.35–12.55)
4.92 (1.15–21.12) 4.10 (0.91–18.47)
1 1
3.12 (1.39–7.03) 2.28 (0.94–5.51)
, lamivudine and efavirenz.
e at ART initiation, weight at treatment initiation, marital status, level of education,
f ART were adjusted for each other.
-3TC-EFV.
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was faster among women initiating ARTat lower baseline CD4 count.
It is well known that having a CD4 count within the normal range
among HIV infected individuals is associated with lower risk of HIV-
related illnesses (Le et al., 2013; Baker et al., 2008) and a greater life
expectancy (May et al., 2014).
Although the beneﬁt of early initiation of ART has been
demonstrated by clinical trials (Group TAS, 2015; Group ISS, 2015),
the beneﬁt was not uniform across various patient groups. In
addition, it is not certain that the observed effectiveness in clinical
trials can be replicated in different real program settings in low
income settings. Moreover, the types of ART regimens used in
clinical trials were not common in low income settings which
make generalization of the ﬁndings to these settings problematic.
Therefore, observational studies demonstrating the beneﬁt of early
ART in real clinical settings are necessary. Our study showed that
early initiation of ART may be beneﬁcial in preserving or recovering
immunity in resource limited settings. The ﬁnding ease the
concerns that early ART may not be effective for asymptomatic
adults with high level CD4 count and supports the recent
recommendations of early initiation of ART for all HIV-infected
individuals by the WHO (WHO, 2016). Previous studies also
reported that initiating ART when the CD4 count is 500 cells/
mm3 compared to deferring treatment until the CD4 drops below
500 cells/mm3 signiﬁcantly increases the likelihood of CD4
normalization (Gras et al., 2007; García et al., 2004; Okulicz
et al., 2015). The beneﬁt of early initiation of treatment is further
reinforced by previous ﬁndings which showed that early initiation
of ART preserves immune function (Le et al., 2013).
On average CD4 count increased across all baselines CD4
categories during follow-up. However, the rate of CD4 count
increase during follow-up was higher among women who initiated
ART at a lower baseline CD4 count. The ﬁnding is not unexpected as
most women who initiated treatment at higher baseline CD4 count
already have normal or near normal CD4 count, and are therefore
not expected to have large CD4 gains during follow-up. The likely
CD4 count trajectory without treatment is a progressive decline
after a transient increase during the acute HIV infection phase (Le
et al., 2013). Preventing CD4 count decline is the likely beneﬁt of
treatment among women who have high baseline CD4 count.
Previous studies reported inconsistent ﬁndings. Some studies
reported a larger CD4 increase among patients with lower baseline
CD4 count (Lifson et al., 2011; Sempa et al., 2013), and others
demonstrated a similar rate of CD4 increase despite the difference
in baseline CD4 count (Lawn et al., 2006; Lewden et al., 2007).
Our study could not determine the long term change in CD4
count,asthefollow-uptimewasonlytwelvemonths.Findingsfroma
few previous studies evaluating CD4 trajectories over time
demonstrated that the CD4 counts continued to increase up to 3
to 4 years after initiation of ART before reaching a plateau after 4–5
years in all CD4 categories (García et al., 2004; Lifson et al., 2011).
Otherstudies indicatedthattheCD4counts continueto increasefor7
years among those who initiated treatment at CD4 count less than
350 cells/mm3 (Gras et al., 2007; Sempa et al., 2013). However, these
studies did not evaluate the effect of treatment initiation at different
CD4 levels among asymptomatic HIV-infected individuals.
We also evaluated clinical outcomes according to baseline CD4
count. Outcomes such as AIDS deﬁning illnesses and mortality
during follow up period were very rare due to the short follow-up
time. As a result, we considered WHO stage II–IV HIV-related
clinical events in combination. The study demonstrated some
evidence of lower risk of HIV-related clinical events among women
who initiated ART at baseline CD4 count of 500 cells/mm3 as
compared to women who initiated treatment with a CD4 count
below 500 cells/mm3, although the conﬁdence intervals were wide
due to the small number of events.The “90-90-90 treatment target” which aims at diagnosing 90% of
HIV-infected individuals, treating 90% of those diagnosed and achieve
viral suppression for 90% of treated individuals, is a key strategy to
achieve one of the sustainable development goals (SDG) of ending
AIDS as a public health threat by 2030 (UNAIDS, 2014). However, low
level of treatment adherence, loss to follow-up, and drug resistance
needs to be addressed to achieve the SDG goals. ART should be taken
for life with adequate level of adherence to get the desired beneﬁt.
However, asymptomatic individuals with a high level of CD4 count
might have poor adherence and be less motivated to continue
treatment (Nachega et al., 2014). For example, a study in Malawi
reported that 73% of women continued ART treatment three months
after initiation but only 56% were adherent to treatment (Hauser et al.,
2017). Drug resistance is another problem that should be taken into
account. The 2017 WHO HIV drug resistance report showed that the
level of HIVdrugresistanceamongtheﬁrst linedrugs used in most low
and middle income countries was very high; three of the four sub-
Saharan African countries included in the report had greater than 10%
pretreatment resistance for non-nucleoside reverse transcriptase
inhibitors (NNRTIs) (ranging from 8.1% to 15.4%) (WHO, 2017).
Mathematical modelingestimates showed that ifNNRTI pretreatment
resistance exceeds 10%, and NNRTI-based ART continue to be a ﬁrst-
line treatment in the next 15 years, NNRTI pretreatment resistance
could become responsible for 16% of AIDS deaths (n = 890 000) and 9%
of new HIV infections (n = 450 000) in sub-Saharan Africa alone
(Phillips et al., 2017). Notably, early initiation of treatment is found to
reduce the risk of HIV drug resistance compared to delaying treatment
(Hamers et al., 2012; Fogel et al., 2016).
Our ﬁndings should be understood in the light of the following
limitations. Because of the observational nature of the study,
different confounding factors could bias the ﬁndings; but we were
able to adjust for a broad range of known potential confounders.
We also explore inﬂuence calendar year at the start of ART but we
found no association between calendar year at the start of ART and
treatment outcome. The study was conducted in resource limited
urban settings which might limit its generalizability to other
settings. Moreover, our study was limited by exclusion of a
substantial number of women due to missing information,
although our comparison of characteristics of those excluded
and those included showed that the two groups were very similar.
More women with lower CD4 counts were started on other ART
types compared to TDF-3TC-EFV. This is because of evolution of the
treatment guideline. Before 2013, efavirenz was not recommended
during early pregnancy for fear of side effects; meanwhile
eligibility for ART was based on CD4 count (<350 cell/mm3) or
disease progression. Viral load and CD4 to CD8 ratio which are
important clinical indicators of treatment success were not
measured. Our study was also limited by short follow-up period;
as a result we could not evaluate the long term trend of CD4 count
and clinical outcomes. Notably, previous studies indicated that
most of the CD4 gains in patients on ART were achieved within one
year of treatment (Lifson et al., 2011; Gezie, 2016).
In conclusion, initiation of ART for asymptomatic HIV-infected
pregnant women with CD4 count 500 cells/mm3 was beneﬁcial
to preserve or recover immunity after 12 months of treatment in
resource limited settings. Our ﬁnding supports the recent WHO
recommendations of universal ART for HIV-infected individuals
including pregnant women as early as possible. A large-scale study
on drug toxicity and drug resistance in resource-limited settings
among men and women who initiate ART at different CD4 counts is
warranted.
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